Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Patient Role in Stimulating Chronic Fatigue Syndrome Drug Development

This article was originally published in RPM Report

Executive Summary

The Food & Drug Administration convened a two-day meeting with CFS patients, advocates, clinicians and researchers in late April. One of the speakers invited by FDA was former Lilly corporate strategy exec Bernard Munos. His presentation was part exhortation, part reality check – delivering in straightforward, practical terms how patient groups can step into the drug development process to deliver data for regulators and commercial developers. Here is a transcript of his remarks, lightly edited for clarity.

Advertisement

Related Content

Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting
FDA’s Draft Agenda for the CFS/ME Patient Input Meeting
How Not To Develop A Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS081155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel